… ProQR Announces Strategic Changes to the Management Team and … said Daniel A. de Boer, chief executive officer of ProQR. “As we are moving into late stage development we are … reporting to David Rodman, MD, Executive Vice President of R&D. Aniz is an experienced ophthalmologist and has over 20 …
… ProQR Announces Webcast of Presentation at Upcoming HC … will be accessible from the “Investors & Media” section of ProQR’s website ( www.proqr.com ) under “ Events ” for approximately 30 days …
… ProQR Therapeutics Announces Results for the Fourth Quarter … said Daniel de Boer, Chief Executive Officer of ProQR. "We have advanced QR-010 through preclinical … the Company's IPO on the Nasdaq Global Market, a grant to ProQR's protection foundation, and increased costs reflecting …
… ProQR Appoints John Maraganore, PhD, as Strategic Advisor to … & CAMBRIDGE, Mass., March 07, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a … if any,” said Daniel A. de Boer, Founder and CEO of ProQR. “As the founding CEO of Alnylam, he built and led one …
… ProQR In-licenses Worldwide Rights to Ophthalmology Drug … said Daniel A. de Boer, chief executive officer of ProQR. “By acquiring the rights to QR-1123, we have … will be made in equity and others in cash or equity at ProQR’s discretion, and royalties on net sales of 20% through …
… ProQR lizenziert weltweite Rechte für Arzneimittelkandidaten … für die Augenheilkunde von Ionis Pharmaceuticals ProQR erhält die exklusive weltweite Lizenz für IONIS-RHO-2.5 … LEIDEN (Niederlande), Oct. 30, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR), ein Unternehmen, das …